<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048529</url>
  </required_header>
  <id_info>
    <org_study_id>T-607-006</org_study_id>
    <nct_id>NCT00048529</nct_id>
  </id_info>
  <brief_title>Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tularik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tularik</source>
  <brief_summary>
    <textblock>
      This is a clinical research study of T900607-sodium to determine if it is effective and safe
      in treating gastric cancer and adenocarcinoma of the esophagus. Patients will be treated on a
      weekly basis with an intravenous injection of the study drug.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>September 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>70</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T900607-sodium intravenous</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically or cytologically confirmed diagnosis of gastric cancer or
             adenocarcinoma of the esophagus

          -  Subjects must have received 1-2 regimens of prior chemotherapy

          -  At least 18 years of age

          -  Bidimensionally measurable disease amenable to CT scanning. At least one lesion must
             be least 1 X 1 cm in size.

          -  Karnofsky performance status of at least 70%

          -  Estimated life expectancy of at least 12 weeks

          -  Females of childbearing potential must have a negative pregnancy test and agree to use
             an effective contraceptive

          -  Subject must be able to comply with study procedures and follow-up examinations.

          -  Signed written informed consent

          -  Lab Values (obtained â‰¤ 7 days prior to study enrollment):

               -  ANC at least 1.5x10e9/L, * Platelet count at least 100x10e9/L,

               -  Creatinine within 2 times upper limit of normal * AST and ALT within 5 times
                  upper limit of normal

               -  Bilirubin within 1.5 times upper limit of normal

               -  Albumin great than 2.5 g/dL

        Exclusion Criteria

          -  Severe, concurrent disease, infection or co-morbidity that, in the judgment of the
             investigator, would make the subject inappropriate for enrollment

          -  NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of &lt;50%,
             or acute anginal symptoms

          -  Patients who have received any investigational agent within 4 weeks of enrollment

          -  Patients who are pregnant or breast-feeding

          -  History of prior malignancy other than gastric cancer or adenocarcinoma of the
             esophagus within the last 5 years, except for adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  History of central nervous system metastases or carcinomatous meningitis

          -  Major surgery within 4 weeks of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerrie Boyd</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Oncology Associates</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Research and Treatment Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2002</study_first_submitted>
  <study_first_submitted_qc>November 1, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

